 Curis Inc NASDAQ: CRIS shares are surging in reaction to updated data from its ongoing open-label, single-arm, Phase 12 study of CA-4948 in patients with acute myeloid leukemia AML or high-risk myelodysplastic syndromes MDS. As of data cut off on February 8, in 15 patients 8 MDS and 7 AML, four objective responses were recorded with signs of hematologic recovery, including: One complete response CR, one complete remission with incomplete hematologic recovery CRi with negative minimal residual disease, and two bone marrow CRs. 